Interserve Press Office | Dec 12, 2017
Interserve, the international support services and construction group, has been awarded an £11.5 million contract by Proton Partners International Ltd - the company bringing high energy proton beam therapy to the UK – to build a new £35 million oncology centre in Liverpool, which will be known as the Rutherford Cancer Centre North West.
The agreement is between Interserve and the subsidiary of Proton Partners International, Rutherford Estates North West. Work on site is scheduled to start on January 8, 2018.
The partnership is of strategic importance with its location in the growing £1 billion Knowledge Quarter (KQ) in Paddington Village and will see the construction of a two-storey cancer treatment facility, the Rutherford Cancer Centre North West.
The oncology centre will bring the most advanced treatments in cancer care to the region, including high energy proton beam therapy, as well as the latest technology on the market to deliver radiotherapy, chemotherapy, imaging and diagnostics.
Conventional treatments will be available from 2018 and high-energy proton beam therapy will be available from 2019. The centre will treat up to 500 patients a year and treatment will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.
Phil Shaw, Interserve’s construction director for the North West, said:
“The team’s knowledge, experience, innovation and expertise contributed to winning this contract. We are delighted to be embarking on a journey with Proton Partners International to jointly deliver a successful project”.
Mike Moran, chief executive officer of Proton Partners International, said:
“We are really pleased to announce that we have appointed Interserve, one of the world’s foremost support services and construction companies, as our partners. We are confident that their team will provide the very best quality and expertise in building our Rutherford Cancer Centre in Liverpool”.
– Ends –
For further information about Interserve, please contact:
Group Head of PR, Interserve
01189 60 2285
Media House International
0207 710 0020
Media House International
0207 710 0020
Interserve is one of the world’s foremost support services and construction companies. Our vision is to redefine the future for people and places. Everything we do is shaped by our core values. We are a leader in innovative and sustainable outcomes for our clients and a great place to work for our people. We offer advice, design, construction, equipment, facilities management and frontline public services. We are headquartered in the UK and listed in the FTSE. We have gross revenues of £3.7 billion and a workforce of circa 80,000 people worldwide.
For Interserve news follow: @interservenews
About Proton Partners International Ltd
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company. Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical officer for the company. The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.
For more information on Proton Partners International, please visit: http://proton-int.com/
Follow us on twitter @ProtonPartners
About The Rutherford Cancer Centres
The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.
Treatment at The Rutherford Cancer Centres will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.